China
Africa
Explore chapters and articles related to this topic
Arterial Thrombosis—Diagnosis and Management
Published in E. Nigel Harris, Thomas Exner, Graham R. V. Hughes, Ronald A. Asherson, Phospholipid-Binding Antibodies, 2020
H. Patrick McNeil, Steven A. Krilis, Colin N. Chesterman
The following discussion relates to the management of arterial thrombosis in general. However, it is highly relevant to aPL-associated thrombosis, as intervention in the acute episode may be more fruitful, since in these situations thrombosis has occurred often in a previously normal artery. Similarly, primary and secondary preventative therapy in aPL-associated syndromes is especially indicated due to the ongoing prothrombotic diathesis.
Imaging of Thrombosis
Published in Hau C. Kwaan, Meyer M. Samama, Clinical Thrombosis, 2019
Albert A. Nemcek, Robert L. Vogelzang
Arterial thrombosis is most frequently encountered in two major settings: as mural thrombus formation in the walls of aneurysms and in association with the progression of severe atherosclerotic narrowing to occlusion. Other less common settings in which arterial thrombosis may occur include trauma, radiation injury, arteritis, drug-induced vasospastic disorders, hypercoagulable states, and local causes of arterial compression such as popliteal artery entrapment.
The influence of a blood clot in hemodynamics: A meshless method study
Published in J. Belinha, R.M. Natal Jorge, J.C. Reis Campos, Mário A.P. Vaz, João Manuel, R.S. Tavares, Biodental Engineering V, 2019
M.I.A. Barbosa, J. Belinha, R.M. Natal Jorge
Since arterial thrombosis is the source of a wide variety of cardiovascular diseases, it becomes necessary to develop models to understand and study the influence of a clot or the blood flow in an artery [14]. To understand the normal and pathologic behavior of the vascular system, it is required to have detailed knowledge of blood flow and the response of blood vessels [5]. However, the complexity of the vascular system hinders the analysis and prediction of its behavior. Thus, to obtain this kind of information, numerical studies are essential [3].
Developing human tissue engineered arterial constructs to simulate human in vivo thrombus formation
Published in Platelets, 2023
Jacob Ranjbar, Ying Yang, Alan G.S. Harper
The need for such models is critical for enhancing our understanding of the pathological mechanisms and treatment of both arterial and venous thrombosis. Whilst both involve unwanted blood clotting, arterial and venous thrombosis occur in parts of the circulatory system with significantly different structures –Arterial thrombosis is elicited by atherosclerotic plaque formation and rupture, whilst venous thrombosis is elicited by venous stasis within the pockets of venous valves. Thus in vitro models will need to accurately reproduce the differing vascular geometries, rheology, mechanical and cellular properties of the different sides of the blood circulation that contribute to these distinct pathologies. Although there are currently excellent in vitro models to study venous thrombosis currently being produced [19], in this review we will focus on the
An update on novel therapies for treating patients with arterial thrombosis
Published in Expert Review of Hematology, 2023
Udaya S Tantry, Sanchit Duhan, Eliano Navarese, Bogumil Ramotowski, Parshotam Kundan, Kevin P Bliden, Paul Gurbel
Arterial thrombosis is the formation of a platelet-rich blood clot that may partially or completely impede blood flow and subsequently lead to clinically relevant ischemic complications and death. In patients with advanced atherosclerotic arterial disease, thrombosis occurs at the site of vascular injury due to plaque rupture or erosion. Other factors, including a dysfunctional (prothrombotic) endothelium, inflammation, systemic hypercoagulability and altered arterial shear play important roles (Figure 1) [1,2]. For more than 30 years, the strategies to prevent recurrent arterial thrombotic events have focused on inhibiting platelet activation and aggregation. The pharmacologic management of patients with cardiovascular disease (CVD) has been undergoing a significant paradigm shift in recent years [3,4]. In addition to targeting well established cyclooxygenase-1 enzyme with acetyl salicylic acid (ASA) and P2Y12 receptor inhibitors, new formulations of ASA and P2Y12 receptor inhibitors and novel agents targeting collagen and thrombin pathways are being explored in clinical trials. They may provide more choices to treat patients with arterial thrombosis. The current review aimed to provide updated information on these novel agents.
Current evidence for pharmacologic therapy following stage 1 palliation for single ventricle congenital heart disease
Published in Expert Review of Cardiovascular Therapy, 2022
Meredith C. G. Broberg, Ira M Cheifetz, Sarah T Plummer
Following stage 1 palliation patients are at risk of thrombotic complications [56–58]. The highest prevalence of thrombosis following all types of congenital cardiac surgery is seen in those patients less than one month of age, the age at which most patients with single ventricle anatomy undergo stage 1 palliation [58, 59]. Patients following stage 1 palliation remain hypoxic leading to polycythemia over time and often iron depletion due to the excess demand on iron stores. Such a situation creates less malleable red blood cells that are more prone to thrombosis [60]. Forty-two (42/549; 7.6%) patients in the SVR trial experienced a first-time thrombotic event either during stage 1 hospitalization (35 patients) or following discharge prior to stage 2 palliation (7 patients)[57]. Thrombotic complications include venous thrombosis, arterial thrombosis, stroke, pulmonary embolism, limb ischemia, and shunt occlusion. These complications in patients following congenital cardiac surgery increase mortality risk [58, 61], hospital and ICU length of stay during their initial postoperative stay [59, 61], and cost [59].